HRTX - Heron Therapeutics, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.03
|
Rev Est: $39.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.67
DETAILS
HIGH:
$9.00
LOW:
$5.00
MEDIAN:
$6.00
CONSENSUS:
$6.67
UPSIDE:
511.93%
Market Cap:
172.15M
Volume:
2,683,543
Avg Volume:
1,594,630
52 Week Range:
1-2.68
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.25
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
122
IPO Date:
1987-08-26
EPS (TTM):
-0.09
P/E Ratio:
-17.18
Revenue (TTM):
144.28M
Total Assets:
233.15M
Total Debt:
177.76M
Cash & Equiv:
25.80M
Rev Growth (5Y):
-0.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-5.3%
Debt/Equity:
-5.28
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $-0.05 | $-0.01 | -275.1% | $38.2M | $39.0M | -2.1% |
| 2025-08-08 | $-0.02 | $-0.01 | -100.0% | $37.2M | $39.1M | -4.8% |
| 2025-05-06 | $0.01 | $-0.01 | +200.0% | $38.9M | $38.2M | +1.7% |
| 2025-02-27 | $0.02 | $-0.03 | +166.7% | $40.8M | $36.7M | +11.2% |
| 2024-11-12 | $-0.03 | $-0.03 | -9.1% | $42.3M | $37.4M | +13.1% |
| 2024-08-06 | $-0.06 | $-0.04 | -50.0% | $36.0M | $36.6M | -1.6% |
| 2024-05-07 | $-0.02 | $-0.08 | +75.0% | $34.7M | $35.9M | -3.4% |
| 2024-03-12 | $-0.07 | $-0.15 | +53.3% | $34.2M | $31.0M | +10.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 144.28M | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0 | 0 | 0 |
| Net Income | (13.58M) | (110.56M) | (182.02M) | (220.68M) | (227.28M) | (204.75M) | (178.84M) | (197.48M) | (173.14M) | (97.59M) | (76.37M) | (55.28M) |
| EPS | -0.09 | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 |
| Total Assets | 233.15M | 222.51M | 250.95M | 305.71M | 353.56M | 512.78M | 462.18M | 234.31M | 67.48M | 137.84M | 76.68M | 75.94M |
| Total Debt | 177.76M | 179.63M | 157.48M | 159.50M | 24.61M | 19.79M | 4.57M | 28.68M | 52.91M | 2.22M | 1.60M | 1.02M |
| Cash & Equivalents | 25.80M | 28.68M | 15.36M | 90.54M | 105.14M | 71.90M | 31.84M | 144.58M | 13.41M | 75.18M | 72.67M | 72.29M |
| Operating Cash Flow | (22.53M) | (58.79M) | (146.91M) | (203.35M) | (184.82M) | (124.58M) | (191.81M) | (170.30M) | (134.10M) | (78.53M) | (60.28M) | (40.76M) |
| Free Cash Flow | (24.23M) | (60.33M) | (148.74M) | (206.38M) | (191.63M) | (131.73M) | (200.98M) | (172.85M) | (137.23M) | (79.61M) | (61.72M) | (42.45M) |
| FCF per Share | -0.16 | -0.44 | -1.36 | -2.10 | -2.11 | -1.61 | -2.75 | -3.20 | -3.62 | -2.41 | -2.32 | -2.63 |
| Book Value | (33.65M) | (33.97M) | 13.57M | 77.57M | 236.49M | 403.83M | 370.16M | 131.14M | (21.25M) | 118.11M | 63.06M | 68.94M |
| Cash & ST Investments | 59.28M | 80.41M | 84.85M | 157.58M | 208.49M | 390.97M | 332.37M | 172.38M | 51.14M | 131.17M | 72.67M | 72.29M |
| ROC Equity | N/A | N/A | -13.41 | -2.84 | -0.96 | -0.51 | -0.48 | -1.51 | N/A | -0.83 | -1.21 | -0.80 |